Research Reports

Key takeaways

Revenue remains $0.00 — consistent with Shattuck’s pre-commercial stage and absence of approved products or licensing income.

Operating loss widened 8.0% to -$15.5M, reflecting increased clinical trial expenses and workforce growth as stated in management commentary.

Net loss was -$14.8M (vs. -$13.7M in Q1 FY2025), with diluted EPS improving to -$0.13 from -$0.27 — a change driven by share count dynamics, not profitability.

Net cash used in operating activities was -$13.4M, aligning with ongoing R&D investment and manufacturing process development for clinical materials.

Management explicitly reaffirmed dependence on future equity offerings, debt financings, or collaborations to meet capital needs — no near-term path to self-funding.

Full analysis

Revenue

Shattuck Labs reported $0.00 in revenue for Q1 FY2026, unchanged from Q1 FY2025. This reflects the company’s status as a development-stage biopharmaceutical enterprise with no approved products, no commercialized therapies, and no material licensing or collaboration revenue recognized during the period. As noted in management commentary, revenue generation remains contingent upon successful clinical development, regulatory approval, and eventual commercialization — none of which have occurred.

Operating and Net Loss

Cash Flow from Operations

Net cash used in operating activities totaled -$13.4M, compared to -$12.0M in Q1 FY2025. This increase in cash outflow aligns with management’s stated expectation to continue using cash in operations for clinical trials, nonclinical studies, manufacturing of clinical trial materials, and process development — all core activities underpinning the company’s current stage of development.

STTK · Shattuck Labs, Inc.

Summary

Key takeaways

Full analysis

Revenue

Operating and Net Loss

Cash Flow from Operations

Other Income

Liquidity and Capital Strategy